

In the Claims:

Please delete claims 34, 40, 50, and 51.

Please amend claims 22, 24, 38, 44, and 57 to read as follows:

CLEAN CLAIMS

22. (Amended) A transdermal therapeutic system comprising a detachable protective layer; a pressure-sensitive adhesive reservoir layer; and a backing layer comprising a unidirectional elastic material having an elasticity of at least 20%.

24. (Amended) The transdermal therapeutic system of claim 22 wherein the system is a patch.

38. (Amended) The transdermal therapeutic system of claim 37 wherein the backing material is a polyterephthalic acid diol ester obtainable by the reaction of a starting material selected from the group consisting of ethylene glycol, 1,4-butanediol, 1,4-dihydroxymethylcyclohexane, terephthalic acid, isophthalic acid, adipic acid, azelaic acid, sebacic acid, dimethyl terephthalate, dimethyl azelate, dimethyl sebacate, bisphenol A diglycidyl ether, n-decane-1, 10-dicarboxylic acid, polyethylene glycol, and polybutylene glycol.

44. (Amended) The transdermal therapeutic system of claim 22 wherein the backing layer facing outwardly has a differentiated marking element.

57. (Amended) A method of producing the transdermal therapeutic system of claim 22 comprising the steps of inserting pressure-sensitive adhesive substance reservoir sections in a sequence in a longitudinal direction into a presupplied strip-like laminate comprising a detachable protective layer and a backing layer

comprising a unidirectional backing material; separating the backing layer by punching;
removing the unwanted cut portion of the backing layers; and separating the protective
layer in the space between the active substance reservoir sections.

Please add the following new claims:

--58. (New) The transdermal therapeutic system of claim 22 wherein the
backing layer comprises a material selected from the group consisting of a woven fabric,
a nonwoven fabric and a film.

59. (New) The transdermal therapeutic system of claim 39 wherein the active
ingredient is selected from the group consisting of oestriol, buprenorphine and a
parasympathomimetic.

60. (New) The transdermal therapeutic system of claim 59, wherein the
parasympathomimetic active ingredient is selected from the group consisting of choline
esters, alkaloids and choline esterase inhibitors.

61. (New) The transdermal therapeutic system of claim 60, wherein the
choline esters are selected from the group consisting of acetylcholine, bethanechol,
carbachol and methacholine.

62. (New) The transdermal therapeutic system of claim 60, wherein the
alkaloids are selected from the group consisting of arecoline and its derivatives and
pilocarpine.

63. (New) The transdermal therapeutic system of claim 60, wherein the
choline esterase inhibitors are selected from the group consisting of demacarium bromide,

distigmine bromide, neostigmine, physostigmine, pyridostigmine bromide and galanthamine.

64. (New) The transdermal therapeutic system of claim 60 wherein the parasympathomimetic active ingredients are used in combination with each other.

65. (New) The transdermal therapeutic system of claim 34 wherein the fabric or film comprises pores having a size of at least $400 \mu\text{m}^2$ embracing an areal proportion of between 10% and 50% of said fabric or film.

66. (New) The transdermal therapeutic system of claim 34 wherein the fabric has a number of warp threads in the range of 300 to 350 per 10 cm of unextended fabric and a number of weft threads in the range from 100 to 140 per 10 cm of unextended fabric.

REMARKS

The Office action dated May 31, 2001 is acknowledged. Claims 22-57 are pending in the instant application. According to the Office action, claims 22-57 have been rejected. By the present "Reply to First Office Action," claims 34, 40 and 50 have been deleted and have been replaced by new claims 58, 59, and 60 respectively. New claims 61-66 have been added. Reconsideration is respectfully requested in light of the amendments being made hereby and of the following remarks.

The specification has been re-examined for any further minor errors. Applicant has corrected all errors of which Applicant has become aware. In this regard, a substitute specification is attached in both clean and marked up versions in accordance with 37 CFR 1.121(b)(3).